Effect of a GnRH Analog on Hepatic Steatosis

Menopause increases the risk of metabolic dysfunction-associated steatotic liver disease (MASLD), possibly owing to the abrupt lack of estrogen. Gonadotropin-releasing hormone (GnRH) treatment in endometriosis is regarded as a model of pharmaceutical menopause. Thus, the effect of goserelin acetate, a GnRH analog that results in transient menopause, on hepatic steatosis and fibrosis will be evaluated in this study.

NCT Number	NCT06523530
Lead Sponsor	Aristotle University Of Thessaloniki Collaborators: 424 General Military Hospital
Conditions	Metabolic Dysfunction-Associated Steatotic Liver Disease, Nonalcoholic Fatty Liver, Endometriosis
Enrollment	62 participants
Start Date	2024-11-26
Primary Completion	2027-04 (estimated)
Study Completion	2027-10 (estimated)
Updated on ClinicalTrials.gov	2026-07-23